Showing results (51-60 of 215) with videos related to

Sort By:
Pageof 22
Physics in Medicine and Biology|April 6, 2006
Polymer gel dosimetry for the TG-43 dosimetric characterization of a new 125I interstitial brachytherapy seedP Papagiannis, E Pantelis, E Georgiou, et al.
European Journal of Cancer Care|February 13, 2010
Occupational health and safety of personnel handling chemotherapeutic agents in Greek hospitalsT C Constantinidis, E Vagka, P Dallidou, et al.
Fertility and Sterility|April 1, 1997
The combination of testosterone undecanoate with tamoxifen citrate enhances the effects of each agent given independently on seminal parameters in men with idiopathic oligozoospermiaD A Adamopoulos, S Nicopoulou, N Kapolla, et al.
Gut|December 1, 1992
Oesophageal motor function before and after healing of oesophagitisP Singh, A Adamopoulos, R H Taylor, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2000
Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatinS Kakolyris, C Kouroussis, K Kalbakis, et al.
Fertility and Sterility|July 1, 1994
Testicular secretion after pulsatile human menopausal gonadotropin therapy in gonadotropin-releasing hormone agonist desensitized dysspermic menD A Adamopoulos, S Nicopoulou, N Kapolla, et al.
Anticancer Research|January 1, 1981
The incidence of positive oestrogen and progesterone receptors in breast cancer of Greek womenS Vassilaros, D A Adamopoulos, J Papadiamantis, et al.
Physics in Medicine and Biology|March 30, 2001
Narrow stereotactic beam profile measurements using N-vinylpyrrolidone based polymer gels and magnetic resonance imagingE Pappas, I Seimenis, A Angelopoulos, et al.
Cancer|May 1, 1999
Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinomaA Makris, T J Powles, S Kakolyris, et al.
Lung Cancer (Amsterdam, Netherlands)|December 18, 2001
Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancerS Kakolyris, C Kouroussis, J Souglakos, et al.
Pageof 22